Literature DB >> 19330263

High levels of serum mannose-binding lectin are associated with the severity of clinical signs of leptospirosis.

K A Miranda1, L R S Vasconcelos, L C B B Coelho, J L Lima Filho, M S M Cavalcanti, P Moura.   

Abstract

The clinical heterogeneity observed in leptospirosis may be associated with host factors or bacteria virulence. Human serum mannose-binding lectin (MBL) recognizes many pathogens, and low levels of this lectin are associated with susceptibility to infection. MBL is also implicated in the modulation of the inflammatory process. We determined the levels of serum MBL during leptospirosis infection. A double-antibody sandwich ELISA was used to detect the immunoreactive serum MBL. The ELISA plates were coated with monoclonal antibody to MBL and bound MBL or recombinant human MBL were detected by rabbit anti-human MBL serum. HRPO-conjugated goat anti-rabbit antibody was used for detection of the reaction. Two groups of patients seen at referral hospitals in Recife, PE, Brazil, were divided according to the year of infection, 2001 (N = 61) or 2002 (N = 57) and compared in terms of disease severity and levels of serum MBL. A group of healthy volunteers (N = 97) matched by age, gender, and ethnic background was used as control. Patients infected in 2001 had more severe outcomes than those infected in 2002, including jaundice, hemorrhage, respiratory alteration, and renal complication (P = 0.0009; chi-square test). The frequency of patients producing serum MBL >1000 ng/mL was higher in the 2001 group than in the 2002 and control groups (P < 0.01), suggesting an association of MBL level with disease severity. The involvement of MBL and genetic variation of the MBL2 gene should be further evaluated to establish the role of this lectin in the pathogenesis of leptospirosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330263     DOI: 10.1590/s0100-879x2009000400007

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  6 in total

1.  Differences in clinical manifestations of imported versus autochthonous leptospirosis in Austria and Germany.

Authors:  Bodo Hoffmeister; Gabriele Peyerl-Hoffmann; Sven Pischke; Ines Zollner-Schwetz; Robert Krause; Matthias C Müller; Angelika Graf; Stefan Kluge; Gerd D Burchard; Winfried V Kern; Norbert Suttorp; Jakob P Cramer
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

Review 2.  Current immunological and molecular tools for leptospirosis: diagnostics, vaccine design, and biomarkers for predicting severity.

Authors:  Senaka Rajapakse; Chaturaka Rodrigo; Shiroma M Handunnetti; Sumadhya Deepika Fernando
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-01-16       Impact factor: 3.944

3.  Mannose-Binding Lectin Serum Levels in Patients With Candiduria.

Authors:  Maryam Moslem; Ali Zarei Mahmoudabadi; Mahnaz Fatahinia; Alireza Kheradmand
Journal:  Jundishapur J Microbiol       Date:  2015-12-26       Impact factor: 0.747

4.  Serum profiling of leptospirosis patients to investigate proteomic alterations.

Authors:  Rajneesh Srivastava; Sandipan Ray; Vineet Vaibhav; Kishore Gollapalli; Tulip Jhaveri; Santosh Taur; Snigdha Dhali; Nithya Gogtay; Urmila Thatte; Rapole Srikanth; Sanjeeva Srivastava
Journal:  J Proteomics       Date:  2012-04-17       Impact factor: 4.044

5.  Association of mannose-binding lectin 2 gene polymorphisms with Guillain-Barré syndrome.

Authors:  Israt Jahan; Shoma Hayat; Mir M Khalid; Rijwan U Ahammad; Asaduzzaman Asad; Badrul Islam; Quazi D Mohammad; Bart C Jacobs; Zhahirul Islam
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

6.  Assessment of Serum Macrophage Migration Inhibitory Factor (MIF) as an Early Diagnostic Marker of Leptospirosis.

Authors:  Krishnamoorthi Sumaiya; Charles Solomon Akino Mercy; Gangatharan Muralitharan; Abdurahman Hajinur Hirad; Abdullah A Alarfaj; Kalimuthusamy Natarajaseenivasan
Journal:  Front Cell Infect Microbiol       Date:  2022-02-14       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.